In 2023 AVeta Medical is fundraising for Pre-seed of $1M+ to bring our innovative AVeta device through FDA clearance & conduct US First in Woman clinical trial.
High Potential Market!
The Total Market Potential of Vaginal Atrophy in EU & US is €2.5bn.
Learn More...
If you are an investor and interested in learning more about the AVeta Medical investment opportunity, please complete the form below and you will be contacted by our CEO.
Our Solution
A Revolutionary Device
“With a price point equivalent to vaginal hormone therapy, I see AVeta as disruptive technology”